Literature DB >> 24818705

ICD programming to reduce shocks and improve outcomes.

Valentina Kutyifa1, Wojciech Zareba, Arthur J Moss.   

Abstract

Despite the clinical benefit of implantable cardioverter defibrillator (ICD), there is a high frequency of inappropriate ICD therapy associated with impaired quality of life, unwanted health care resource utilization, and adverse clinical outcome. Alternative strategies of ICD programming are needed to reduce the risk of inappropriate and "unnecessary" ICD therapies and to improve patient outcome. In this review, we provide an overview of the rate of inappropriate and appropriate ICD therapies in clinical trials and large registries as well as a review of current trials evaluating novel ICD programming to reduce inappropriate ICD therapy to avoid unnecessary ICD therapy. Based on recent studies including a large randomized trial, we recommend a simple programming approach involving high-rate device therapy beginning at 200 bpm with a 2.5 sec delay for it reduces inappropriate therapy, unnecessary therapy, and all-cause mortality in patients receiving ICD or CRT-D devices for primary prevention indications.

Entities:  

Mesh:

Year:  2014        PMID: 24818705     DOI: 10.1007/s11886-014-0496-1

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  39 in total

1.  Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience.

Authors:  Mika Lehto; Steven Snapinn; Kenneth Dickstein; Karl Swedberg; Markku S Nieminen
Journal:  Eur Heart J       Date:  2004-12-09       Impact factor: 29.983

2.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

3.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

4.  Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial.

Authors:  Michael O Sweeney; Mark S Wathen; Kent Volosin; Ismaile Abdalla; Paul J DeGroot; Mary F Otterness; Alice J Stark
Journal:  Circulation       Date:  2005-05-31       Impact factor: 29.690

5.  Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.

Authors:  Arthur J Moss; Henry Greenberg; Robert B Case; Wojciech Zareba; W Jackson Hall; Mary W Brown; James P Daubert; Scott McNitt; Mark L Andrews; Adam D Elkin
Journal:  Circulation       Date:  2004-12-06       Impact factor: 29.690

6.  Avoid delivering therapies for nonsustained fast ventricular tachyarrhythmia in patients with implantable cardioverter/defibrillator: the ADVANCE III Trial.

Authors:  Joerg O Schwab; Maurizio Gasparini; Maurizio Lunati; Alessandro Proclemer; Bernd Kaup; Elisabetta Santi; Guiseppe Ligorio; Catherine Klersy; João DE Sousa; Andrzej Okreglicki; Angel Arenal; Maurits Wijffels; Bernd Lemke
Journal:  J Cardiovasc Electrophysiol       Date:  2009-01-09

7.  Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.

Authors:  James P Daubert; Wojciech Zareba; David S Cannom; Scott McNitt; Spencer Z Rosero; Paul Wang; Claudio Schuger; Jonathan S Steinberg; Steven L Higgins; David J Wilber; Helmut Klein; Mark L Andrews; W Jackson Hall; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2008-04-08       Impact factor: 24.094

8.  Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.

Authors:  Sana M Al-Khatib; Anne Hellkamp; Gust H Bardy; Stephen Hammill; W Jackson Hall; Daniel B Mark; Kevin J Anstrom; Jeptha Curtis; Hussein Al-Khalidi; Lesley H Curtis; Paul Heidenreich; Eric D Peterson; Gillian Sanders; Nancy Clapp-Channing; Kerry L Lee; Arthur J Moss
Journal:  JAMA       Date:  2013-01-02       Impact factor: 56.272

9.  Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.

Authors:  Bruce L Wilkoff; Brian D Williamson; Richard S Stern; Stephen L Moore; Fei Lu; Sung W Lee; Ulrika M Birgersdotter-Green; Mark S Wathen; Isabelle C Van Gelder; Brooke M Heubner; Mark L Brown; Keith K Holloman
Journal:  J Am Coll Cardiol       Date:  2008-08-12       Impact factor: 24.094

10.  Gross and microscopic pathological changes associated with nonthoracotomy implantable defibrillator leads.

Authors:  A E Epstein; G N Kay; V J Plumb; S M Dailey; P G Anderson
Journal:  Circulation       Date:  1998-10-13       Impact factor: 29.690

View more
  2 in total

1.  Different impact of long-detection interval and anti-tachycardia pacing in reducing unnecessary shocks: data from the ADVANCE III trial.

Authors:  Angel Arenal; Alessandro Proclemer; Axel Kloppe; Maurizio Lunati; José Bautista Martìnez Ferrer; Ahmad Hersi; Marcin Gulaj; Maurits C E F Wijffels; Elisabetta Santi; Laura Manotta; Lorenza Mangoni; Maurizio Gasparini
Journal:  Europace       Date:  2016-08-02       Impact factor: 5.214

2.  Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network.

Authors:  Robert T Greenlee; Alan S Go; Pamela N Peterson; Andrea E Cassidy-Bushrow; Charles Gaber; Romel Garcia-Montilla; Karen A Glenn; Nigel Gupta; Jerry H Gurwitz; Stephen C Hammill; John J Hayes; Alan Kadish; David J Magid; David D McManus; Deborah Multerer; J David Powers; Liza M Reifler; Kristi Reynolds; Claudio Schuger; Param P Sharma; David H Smith; Mary Suits; Sue Hee Sung; Paul D Varosy; Humberto J Vidaillet; Frederick A Masoudi
Journal:  J Am Heart Assoc       Date:  2018-03-26       Impact factor: 5.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.